Article
13 Mar 2026
A "New Era" Of Consumer Medicine? FDA Takes Another Swipe At "Unapproved" Compounded Drugs
AUTHORS CONTENT
Article
18 Feb 2026
2026 Top-of-Mind Issues For Life Sciences Companies
Article
05 Feb 2026
Of Drugs And DTC Platforms: American Consumerism, TrumpRx, Telehealth, And The Specter Of Congressional Intervention
Article
12 Sep 2025
FDA's Vast Ad/Promo Warning – Enforcement Ramp-Up Or PR Nothingburger?
Article
01 Aug 2025
DOJ False Claims "Working Group" Update
Article
12 Jun 2025
What To Watch: FDA Shifts Attention On Artificial Intelligence
Article
05 Feb 2025
2025 Top-of-Mind Issues For Life Sciences Companies
Article
19 Dec 2024
LDT Final Rule Series: Part 3 – Legal Challenges
Article
24 Sep 2024
The Future Of FDA Policy: Reflections From The Summer Of 'Chevron'
Article
10 Jun 2024
LDT Final Rule Series: Part 2 – Response To The Rule
Article
30 Apr 2024
FDA Warning Letter Regulates "Research Only" Labels
Article
22 Dec 2023
Tech Support: FDA's Evolving Regulatory Plan For Drug- And Device-Enabling Software
Article
13 Nov 2023
OIG General Compliance Program Guidance November 2023
Article
17 Jan 2023
6 Takeaways From LabSolutions 'Unnecessary Testing' Verdict
Article
10 Jan 2023
Industry Fights Back Against Restrictions On Pharmaceutical Manufacturers' Ability To Offer Drug Cost-Sharing Subsidies
Article
23 Mar 2022
OIG Advisory Opinion Alert: Yet Another Favorable Decision For Medical Device Manufacturers